SAB Biotherapeutics said its Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track, targeting enrollment completion in Q4 2026. The company expects top-line data in H2 2027, which is a modest positive validation of the clinical timeline but not yet a results catalyst.
SAB Biotherapeutics said its Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track, targeting enrollment completion in Q4 2026. The company expects top-line data in H2 2027, which is a modest positive validation of the clinical timeline but not yet a results catalyst.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
